Bimodal Molecule as NIR-CT Contrast Agent for Hepatoma Specific Imaging

Area of Science:

• Biomedical Imaging
• Molecular Imaging
• Nanotechnology in Medicine

Background:

• Hepatocellular carcinoma (HCC) diagnosis is often delayed due to limitations in current molecular imaging sensitivity and liver specificity.
• Lack of effective contrast agents hinders early detection and treatment of liver cancer.

Purpose of the Study:

• To develop and evaluate a novel bimodal contrast agent (CNCI-1) for early hepatocellular carcinoma (HCC) detection.
• To assess the liver specificity and imaging capabilities of CNCI-1 using X-ray computed tomography (CT) and near-infrared (NIR) imaging.

Main Methods:

• Synthesis and characterization of the bimodal contrast agent CNCI-1.
• In vitro and in vivo evaluation in HCC mouse models (HepG2, LM3) using NIR imaging.
• Assessment of CT imaging enhancement in a rabbit VX2 orthotopic hepatoma model.

Main Results:

• CNCI-1 demonstrated high liver specificity and sensitivity in detecting HCC in vivo.
• The agent effectively visualized HCC regions in xenografted and orthotopic hepatoma mouse models via NIR imaging.
• CNCI-1 enhanced CT imaging by revealing tumor-associated vasculature in a rabbit model, proving noninvasive and hepatocarcinoma-preferential.

Conclusions:

• The novel bimodal contrast agent CNCI-1 facilitates early HCC detection with high sensitivity and specificity.
• CNCI-1 offers a promising new strategy for developing advanced medical imaging agents for liver cancer diagnosis.
• This approach provides a new avenue for creating medically relevant bimodal contrast agents for early-stage HCC diagnosis.